Jie Tang

Jie Tang


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Thyroid®
Verified
Journal Article
Closed access
MZMingbo Zhang
Mingbo Zhang
YLYukun Luo
Yukun Luo
YZYan Zhang
Yan Zhang
JTJie Tang
Jie Tang
Background. Papillary thyroid microcarcinoma (PTMC) has a high incidence and a good prognosis. Surgical operation for all PTMC might be an overtreatment. The objective of our study was to evaluate the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treating low risk PTMC. Methods. 98 PTMC in 92 patients were included in our study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before ablation. RFA was performed using the moving shot technique. The ablation area exceeded the tumor edge to prevent marginal residue and recurrence. Patients were followed at one, three, six, and twelve months and every six months thereafter. US and CEUS examinations were used to evaluate the ablation area. At 3 months after ablation, US-guided core needle biopsy (CNB) was performed in the center, at the edge of the ablation area, and in the surrounding thyroid parenchyma, respectively, to exclude recurrence. Results. The mean tumor volume was 118.8±106.9 mm3. The mean volume reduction ratio was 0.47±0.27, 0.19±0.16, 0.08±0.11, 0.04±0.10 and 0 at one month, 3 months, 6 months, 12 months and 18 month after RFA respectively. Significant differences of the volume reduction ratio were found between every two follow-up times before 6 months (P<0.01), and no significant differences of the volume reduction ratio were found between 6 months and after 12 months (P=0.42). Of all the nodules, 10 (41.7%) resolved in 6 months and 23 (95.8%) resolved in 12 months. No residual or recurrent tumor tissue was detected in RFA area or in residual thyroid tissue during follow up. No suspicious metastatic lymph nodes were detected. The histological pathology results of US-guided CNB confirmed no recurrent tumor. No major complications were encountered. Conclusions. RFA can effectively eliminate low risk PTMC with a very small complication rate. RFA may be an alternative strategy for the therapy of PTMC.

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
MWMeng Wu
Meng Wu
HZHongyun Zhao
Hongyun Zhao
LGLiang Guo
Liang Guo
YWYiru Wang
Yiru Wang
JSJiao Song
Jiao Song
JTJie Tang
Jie Tang
The Forkhead box M1 (FoxM1) transcription factor is an important anti-tumor target. A novel targeted ultrasound (US)-sensitive nanobubble that is likely to make use of the physical energy of US exposure for the improvement of delivery efficacy to target tumors and specifically silence FoxM1 expression appears as among the most potential nanocarriers in respect of drug delivery. In this study, we synthesized a promising anti-tumor targeted FoxM1 siRNA-loaded cationic nanobubbles (CNBs) conjugated with an A10-3.2 aptamer (siFoxM1-Apt-CNBs), which demonstrate high specificity when binding to prostate-specific membrane antigen (PSMA) positive LNCaP cells. Uniform nanoscaled siFoxM1-Apt-CNBs were developed using a thin-film hydration sonication, carbodiimide chemistry approaches, and electrostatic adsorption methods. Fluorescence imaging as well as flow cytometry evidenced the fact that the siFoxM1-Apt-CNBs were productively developed and that they specifically bound to PSMA-positive LNCaP cells. siFoxM1-Apt-CNBs combined with ultrasound-mediated nanobubble destruction (UMND) significantly improved transfection efficiency, cell apoptosis, and cell cycle arrest in vitro while reducing FoxM1 expression. In vivo xenografts tumors in nude-mouse model results showed that siFoxM1-Apt-CNBs combined with UMND led to significant inhibition of tumor growth and prolonged the survival of the mice, with low toxicity, an obvious reduction in FoxM1 expression, and a higher apoptosis index. Our study suggests that siFoxM1-Apt-CNBs combined with UMND might be a promising targeted gene delivery strategy for therapy of prostate cancer.

1 July 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
MWMeng Wu
Meng Wu
YWYing Wang
Ying Wang
YWYiru Wang
Yiru Wang
MZMingbo Zhang
Mingbo Zhang
YLYukun Luo
Yukun Luo
ZWZhibiao Wang
Zhibiao Wang
In the current study, we synthesized prostate cancer-targeting poly(lactide-co-glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy.

1 March 2019 in Data Intelligence
Verified
Journal Article
Open access
HWHuaiyu Wan
Huaiyu Wan
YZYutao Zhang
Yutao Zhang
JZJing Zhang
Jing Zhang
JTJie Tang
Jie Tang
AMiner is a novel online academic search and mining system, and it aims to provide a systematic modeling approach to help researchers and scientists gain a deeper understanding of the large and heterogeneous networks formed by authors, papers, conferences, journals and organizations. The system is subsequently able to extract researchers’ profiles automatically from the Web and integrates them with published papers by a way of a process that first performs name disambiguation. Then a generative probabilistic model is devised to simultaneously model the different entities while providing a topic-level expertise search. In addition, AMiner offers a set of researcher-centered functions, including social influence analysis, relationship mining, collaboration recommendation, similarity analysis, and community evolution. The system has been in operation since 2006 and has been accessed from more than 8 million independent IP addresses residing in more than 200 countries and regions.

3 March 2022 in Drug Delivery
Verified
Journal Article
Open access
DWDingyi Wang
Dingyi Wang
ZWZhuo Wan
Zhuo Wan
QYQian Yang
Qian Yang
JCJianmei Chen
Jianmei Chen
YLYunnan Liu
Yunnan Liu
JTJie Tang
Jie Tang
Prostate cancer (PCa) responds poorly to routine immunotherapy due to the tumor immunosuppressive microenvironment. Here, we describe an ultrasound-based drug delivery strategy to stimulate potent anti-tumor immunity via exosomes encapsulated with sonosensitizers Chlorin e6 (Ce6) and immune adjuvant R848, namely ExoCe6+R848. ExoCe6+R848 was constructed by simple co-incubation of Ce6 and R848 with HEK 293T cell-derived exosomes. The properties of exosomes were not affected after loading Ce6 and R848, and the exosomes were accumulated in the tumor site after intratumoral injection. In vitro and in vivo assays showed that ultrasonic irradiation enhanced R848-mediated DCs maturation when ExoCe6+R848 was engulfed by DCs, as demonstrated by the upregulated expression of CD80 and CD86. Furthermore, these engineered exosomes together with ultrasound irradiation could synergistically reprogram macrophages from an immunosuppressive M2-like phenotype to an anti-tumor M1-like phenotype, further activating effector T cells and reverting the immunosuppressive microenvironment. The exosome delivery strategy not only supplies a paradigm for overcoming side effects of systemic delivery of Ce6 and R848, but also offers an effective combination regimen of cancer immunotherapy.

11 January 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LGLiang Guo
Liang Guo
YMYa-Qi Ma
Ya-Qi Ma
YYYao Yao
Yao Yao
MWMeng Wu
Meng Wu
ZDZi-Hui Deng
Zi-Hui Deng
JTJie Tang
Jie Tang
The association between cervical lymph node metastasis (LNM) and ultrasonographic features as well as BRAFV600E mutations in patients with papillary thyroid carcinoma (PTC) remained controversial. This study investigated the association between LNM and ultrasonographic features as well as BRAFV600E mutation in Chinese patients with PTC. A total of 280 patients with PTC in China were included in this study. 108 had cervical lymph node metastasis, while 172 had not. Younger age (<45years) and several ultrasonographic features were significantly associated with cervical LNM (Ps < 0.05). The BRAFV600E mutation was detected in 81.0% of patients with PTC (226/280). The status of BRAFV600E mutation was not associated with cervical LNM. However, Ct values by PCR and intensity of reactions by immunohistochemistry (IHC) for BRAFV600E expression had shown significant difference between group with and without LNM. Furthermore, an increased proportion of LNM was also found with the incremental intensity of IHC for BRAFV600E expression from weak to strong reaction after adjusted potential confounders. Further studies are required to verify this association and explore the intrinsic mechanism.